Skip to main content

Education/ACR/EULAR

      RT @philipcrobinson: Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec sli
      4 years 6 months ago
      Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4
      RT @philipcrobinson: Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%,
      4 years 6 months ago
      Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
      RT @RichardPAConway: And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #
      4 years 6 months ago
      And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L
      RT @DrPetryna: #Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of
      4 years 6 months ago
      #Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow
      RT @drdavidliew: Enticing stuff. Avacopan wins on 52w remission, steroid toxicity/use, renal fx, with minimal toxicity.
      4 years 6 months ago
      Enticing stuff. Avacopan wins on 52w remission, steroid toxicity/use, renal fx, with minimal toxicity. Looks good to be a steroid replacement in AAV, with real benefit for patients. Exciting but cost will dictate if we get to use it (see: apremilast) OP0011 #EULAR2020 @RheumNow https://t.co/WTFk21D0KY
      RT @KDAO2011: #EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (9
      4 years 6 months ago
      #EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status. @RheumNow https://t.co/Hkv6T7pl9f
      RT @KDAO2011: #EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA
      4 years 6 months ago
      #EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq
      RT @KDAO2011: #EULAR2020 ABST#OP0015Plenary session: very low serum urate < 4 mg/dL in men assc w/increased CV mortal
      4 years 6 months ago

      #EULAR2020 ABST#OP0015Plenary session: very low serum urate < 4 mg/dL in men assc w/increased CV mortality; 40,000 pt study. NOTE: this may be driven by poorly controlled diabetes as hyperglycemia has a uricosuric effect; from NHANES database @MassGeneralNews @RheumNow https://t.co/jnhkS436JZ

      RT @KDAO2011: #EULAR2020 Plenary Abstr#OP0016 Brilliant study showed how gut microbiota dysbiosis may trigger RA in high
      4 years 6 months ago
      #EULAR2020 Plenary Abstr#OP0016 Brilliant study showed how gut microbiota dysbiosis may trigger RA in high risk people (+CCP w/o Sx) using fecal transplantation in a mouse model to trigger collagen induced arthritis @rheumnow Healthy vs. preclin RA vs. RA microbiota specimen: https://t.co/ZITCAcmuXh
      RT @KDAO2011: #EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial
      4 years 6 months ago
      #EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ
      ×